Read the primary source rather than the write-up and the two do not agree, so here is what is actually in it.
The apnoea data is some of the strongest non-weight evidence in the class. SURMOUNT-OSA showed large reductions in apnoea-hypopnoea index on tirzepatide, with a meaningful fraction of participants improving enough to change their treatment category. Mechanistically it is upper-airway fat and reduced abdominal load rather than anything neurological, which is why the effect tracks weight loss closely.
Where I think it is weakest: the follow-up is short relative to how long people actually take these drugs, so durability is an assumption here rather than a finding.
So the question, as narrowly as I can put it: what people did about re-titration, because feeling better is not the same as a study saying you are better. Happy to be told the question itself is wrong.
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
SleepDoc_PDX said:The apnoea data is some of the strongest non-weight evidence in the class.
True, though the ladder is longer and that is not a neutral detail — six dose steps means six opportunities to stall on the way up, and plenty of people never reach the dose the headline number came from.
SleepDoc_PDX said:The apnoea data is some of the strongest non-weight evidence in the class.
I read this differently from SleepDoc_PDX, on substance rather than tone. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.
Ask again with the specifics and you will get a better answer than this one.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsAnswering the narrow version, because the broad one does not have a single answer. Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five. That matters when you are deciding whether a dose step has finished expressing itself.
Dr.GutHealth said:True, though the ladder is longer and that is not a neutral detail — six dose steps means six opportunities to stall on the way up, and plenty of…
Second this. Nothing to add that would improve it.